77 / 210
Ponencias
77
the ISPOR Real-World Data Task Force report. Value Health
2007;10(5):326-35.
2. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N,
Ezekowitz MD, et al. Comparison of the efficacy and safety of new
oral anticoagulants with warfarin in patients with atrial fibrillation: a
meta-analysis of randomised trials. Lancet 2014;383(9921):955-62.
3. Laliberte F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson
WH, et al. Real-world comparative effectiveness and safety of
rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.
Current medical research and opinion 2014;30(7):1317-25.
4. Beyer-Westendorf J, Forster K, Pannach S, Ebertz F, Gelbricht V,
Thieme C, et al. Rates, management, and outcome of rivaroxaban
bleeding in daily care: results from the Dresden NOAC registry.
Blood 2014;124(6):955-62.
5. Tamayo S, Frank PeacockW, Patel M, Sicignano N, Hopf KP, Fields
LE, et al. Characterizing major bleeding in patients with nonvalvu-
lar atrial fibrillation: a pharmacovigilance study of 27 467 patients
taking rivaroxaban. Clin Cardiol 2015;38(2):63-8.
6. Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, et al.
XANTUS: a real-world, prospective, observational study of patients
treated with rivaroxaban for stroke prevention in atrial fibrillation.
Eur Heart J 2015.
7. Coleman CI, Antz M, Ehlken B, Evers T. REal-LIfe Evidence of
stroke prevention in patients with atrial Fibrillation-The RELIEF
study. International journal of cardiology 2016;203:882-4.
8. Hecker J, Marten S, Keller L, Helmert S, Michalski F, Werth S, et al.
Effectiveness and safety of rivaroxaban therapy in daily-care patients
with atrial fibrillation. Results from the Dresden NOAC Registry.
Thromb Haemost 2016;115(5):939-49.
9. Larsen TB, Rasmussen LH, Skjoth F, Due KM, Callreus T, Rosen-
zweig M, et al. Efficacy and safety of dabigatran etexilate and war-
farin in “real-world” patients with atrial fibrillation: a prospective
nationwide cohort study. J Am Coll Cardiol 2013;61(22):2264-73.
10. Beyer-Westendorf J, Ebertz F, Forster K, Gelbricht V, Michalski F,
Kohler C, et al. Effectiveness and safety of dabigatran therapy in
daily-care patients with atrial fibrillation. Results from the Dresden
NOAC Registry. Thromb Haemost 2015;113(6).
11. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR,
Levenson M, et al. Cardiovascular, bleeding, and mortality risks in
elderly Medicare patients treated with dabigatran or warfarin for
nonvalvular atrial fibrillation. Circulation 2015;131(2):157-64.
12. Korenstra J, Wijtvliet EP, Veeger NJ, Geluk CA, Bartels GL, Posma
JL, et al. Effectiveness and safety of dabigatran versus acenocouma-
rol in ‘real-world’ patients with atrial fibrillation. Europace 2016.
13. Deitelzweig S, BrunoA, Trocio J, Tate N, Gupta K, Lin J, et
al.Anearly
evaluation of bleeding-related hospital readmissions among hospitalized
patients with nonvalvular atrial fibrillation treated with direct oral anti-
coagulants. Current medical research and opinion 2016;32(3):573-82.
14. Fontaine GV, Mathews KD, Woller SC, Stevens SM, Lloyd JF, Evans
RS. Major bleeding with dabigatran and rivaroxaban in patients with
atrial fibrillation: a real-world setting. Clinical and applied throm-
bosis/hemostasis: official journal of the International Academy of
Clinical and Applied Thrombosis/Hemostasis 2014;20(7):665-72.
15. Southworth MR, Reichman ME, Unger EF. Dabigatran and post-
marketing reports of bleeding. N Engl J Med 2013;368(14):1272-4.
16. Hernández I, Baik SH, Pinera A, Zhang Y. Risk of bleeding with
dabigatran in atrial fibrillation. JAMA Intern Med 2015;175(1):
18-24.
17. Labaf A, Carlwe M, Svensson PJ. Efficacy and safety of novel oral
anticoagulants in clinical practice: a report from three centers in
Sweden. Thromb J 2014;12(1):29.
18. Chang HY, Zhou M, Tang W, Alexander GC, Singh S. Risk of gas-
trointestinal bleeding associated with oral anticoagulants: population
based retrospective cohort study. Bmj 2015;350:1585.
19. Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W,
et al. Comparative risk of gastrointestinal bleeding with dabiga-
tran, rivaroxaban, and warfarin: population based cohort study. Bmj
2015;350:1857.
20. Sipahi I, Celik S, Tozun N. A comparison of results of the US food
and drug administration’s mini-sentinel program with randomized
clinical trials: the case of gastrointestinal tract bleeding with dabi-
gatran. JAMA Intern Med 2014;174(1):150-1.
21. Nishtala PS, Gnjidic D, Jamieson HA, Hanger HC, Kaluarachchi C,
Hilmer SN. ‘Real-world’ haemorrhagic rates for warfarin and dabi-
gatran using population-level data in New Zealand. International
journal of cardiology 2016;203:746-52.
22. Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA,
Fang G. Effectiveness and safety of dabigatran and warfarin in real-
world US patients with non-valvular atrial fibrillation: a retrospective
cohort study. Journal of the American Heart Association 2015;4(4).
23. Halbritter K, Beyer-Westendorf J, Nowotny J, Pannach S, Kuhlisch
E, Schellong SM. Hospitalization for vitamin-K-antagonist-rela-
ted bleeding: treatment patterns and outcome. J Thromb Haemost
2013;11(4):651-9.
24. Gomes T, Mamdani MM, Holbrook AM, Paterson JM, Hellings C,
Juurlink DN. Rates of hemorrhage during warfarin therapy for atrial
fibrillation. Cmaj 2013;185(2):E121-7.
25. Larsen TB, Gorst-Rasmussen A, Rasmussen LH, Skjoth F, Rosen-
zweig M, Lip GY. Bleeding events among new starters and switchers
to dabigatran compared with warfarin in atrial fibrillation. Am J Med
2014;127(7):650-6 e5.
26. Caldeira D, Rodrigues FB, Barra M, Santos AT, de Abreu D, Goncal-
ves N, et al. Non-vitamin K antagonist oral anticoagulants and major
bleeding-related fatality in patients with atrial fibrillation and venous
thromboembolism: a systematic review and meta-analysis. Heart
2015;101(15):1204-11.
27. Leef G, Qin D, Althouse A, Alam MB, Rattan R, Munir MB, et al.
Risk of Stroke and Death inAtrial Fibrillation by Type of Anticoagu-
lation: A Propensity-Matched Analysis. Pacing Clin Electrophysiol
2015;38(11):1310-6.